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Abstract
Purpose: To analyze the outcome after adjuvant radiation therapy with standard fractionation regimen in
metastatic lymph nodes (LN) from cutaneous melanoma.
Patients and methods: 86 successive patients (57 men) were treated for locally advanced melanoma in our
institution. 60 patients (69%) underwent LN dissection followed by radiation therapy (RT), while 26 patients (31%)
had no radiotherapy.
Results: The median number of resected LN was 12 (1 to 36) with 2 metastases (1 to 28). Median survival after the
first relapse was 31.8 months. Extracapsular extension was a significant prognostic factor for regional control (p =
0.019). Median total dose was 50 Gy (30 to 70 Gy). A standard fractionation regimen was used (2 Gy/fraction).
Median number of fractions was 25 (10 to 44 fractions). Patients were treated with five fractions/week. Patients
with extracapsular extension treated with surgery followed by RT (total dose ≥50 Gy) had a better regional control
than patients treated by surgery followed by RT with a total dose <50 Gy (80% vs. 35% at 5-year follow-up; p =
0.004).
Conclusion: Adjuvant radiotherapy was able to increase regional control in targeted sub-population (LN with
extracapsular extension).
Introduction
The incidence of cutaneous melanoma is increasing in
fair-skinned populations. Surgery is the main treatment
for melanoma and has a central role in the management
of many patients [1]. Despite appropriate excision, locally
invasive melanomas bring risks of both local and distant
relapses [2]. While distant metastasis is often considered
as the main factor for overall survival, regional control is
still very important for the quality of life of these patients
(figure 1). Systemic therapies for metastatic patients have
led to modest improvements in locoregional control or
overall survival [3]. Other ways to improve patients’ sur-
vival have been explored in vain. The use of sentinel
lymph node (SL) is gaining popularity in staging and
treatment of patients with melanoma [4]. However, even
with this approach, no survival benefit from SL with sub-
sequent radical regional lymphadenectomy in malignant
melanoma patients with lymph node (LN) metastases
was found [5]. Additional treatments are therefore
needed to improve the patient’s outcome for melanomas
with a high risk of locoregional or distant recurrence.
Radiation therapy forms the third cornerstone of can-
cer management, together with surgery and systemic
treatments. Although the role of radiotherapy in achiev-
ing locoregional control and palliation is recognised, it
is not often used for the management of melanoma. Use
of radiation therapy for these patients has been hindered
by the belief that melanoma is resistant to radiation [6].
This point of view is not shared by everyone [7].
Several retrospective studies on radiation therapy for the
management of metastatic lymph nodes from cutaneous
melanoma have been published [8-12]. They showed the
benefit of radiation therapy in preventing local recurrence
in metastatic lymph nodes from cutaneous melanoma
after lymphadenectomy. This treatment had no impact on
disease-free survival or overall survival. Most of these
retrospective studies used a hypofractionated radiation
regimen (30 Gy in 5 fractions).
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regimen for the management of these patients. In this
study, we reviewed our experience in the treatment of
locally advanced melanoma in order to identify prognos-
tic factors. We tried to assess whether adjuvant radiation
therapy was advantageous in locally advanced melanoma,
which minimal dose and radiation regimen should be
used, and for which patients it should be used.
Material and methods
Patients
Between 2000 and 2009, 86 successive patients were
diagnosed with lymph node metastases from melanoma
and treated with lymphadenectomy, followed by or with-
out radiation therapy, and without systemic therapy.
Having four or more involved lymph nodes, extracap-
sular extension and node size greater than 3 centimetres
were our main indications for radiation therapy in this
study. Patients with visceral metastases at the time of
RT were excluded from the analysis.
Technical features of radiation therapy
Three-dimensional conformal radiation therapy was used.
Areas treated included the axillary, cervical and groin
lymph node areas. Organs at risk were contoured accord-
ing to locations: for the axillary area: lung, heart, head of
homolateral humerus; for cervical lymph nodes: parotid,
larynx, thyroid; for groin lymph nodes: homolateral femoral
head, rectum, bladder. Radiation was delivered by X-rays.
Follow-up
Tumour relapse was established on the base of any clin-
ical or radiological evidence of relapse. Any dermal,
subcutaneous, soft tissue or lymph node relapse within
or around the dissected and irradiated nodal basin was
considered to be a local recurrence. The toxicity was
analyzed using the grading scale introduced by Ballo
et al in 2006 [9]. The classification consisted in grade 1
toxicity for an asymptomatic finding noted at the time
of the follow-up physical examination; grade 2 for a
symptomatic finding requiring any form of medical ther-
apy (e.g., compressive sleeve for lymphedema, physical
therapy for neuropathy, or long-term use of pain medi-
cation); and grade 3 for toxicity requiring surgical inter-
vention. The follow-up period and survival were
calculated from the date of surgery to November 2009.
Statistical method
The distribution of categorical variables was tested using
a Fisher exact test and chi-square test for trends. The
primary endpoint was regional control, which was
defined as complete and permanent eradication of
tumour in treated area. The secondary endpoint was
overall survival. We carried out 3 successive analyses: (i)
an identification of prognostic factors on the whole
cohort (ii) a crude survival analysis according to the
treatment performed (iii) a stratified survival analysis
according to prognostic factor(s) identified.
Univariate analysis of the patients’ survival was carried
out using the Kaplan-Meier method with 95% confi-
dence intervals (CI) and a log-rank comparison to evalu-
ate the difference between the survival curves.
Univariate analysis was performed according to Cox’s
proportional hazard. All statistical tests were two-sided,
and a p value of <0.05 was considered statistically signif-
icant. The statistical package SPSS 13.0 (SPSS Inc.,
Chicago, IL, USA) was used to perform the analysis.
Results
Patient characteristics
Eighty-six patients were treated for metastatic lymph
nodes from melanoma between August 1996 and
November 2009. Fifty-seven were men. The median age
at which the melanoma was diagnosed was 51 years (18
to 87 years). The median Breslow index was 2.5 mm
(0.15 to 33 mm). The Clark level was known in 66
patients and was: level I in 1 patient, level II in 1
patient, level III in 16 patients, level IV in 44 patients
and level V in 4 patients. Ulceration of the primary
tumour was found in 12 patients. Initial treatment was
not known for 2 patients. Seventy-nine patients had a
complete resection of the initial melanoma (92%). Three
patients had lymphadenectomy (3.4%) only, and 4
patients had concomitant resection of melanoma and
lymphadenectomy (4.6%).
The clinical and pathologic characteristics are presented
in Table 1. Median time lapse between initial diagnosis
Figure 1 Inflammatory axillary nodal recurrence from
cutaneous melanoma.
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months). Median age when lymph node metastases were
diagnosed was 52 years old (19 to 87 years old). The sites
of the metastatic lymph nodes were: 20 cervical (23.3%),
26 axillary (30.2%) and 40 inguinal (46.5%). Twenty-six
patients (30%) had no radiation therapy (group 1). Sixty
patients (70%) underwent lymphadenectomy followed by
conformal radiation therapy: 30 patients were treated with
a total dose <50 Gy (group 2) and 30 patients with a total
dose >50 Gy (group 3).
No systemic therapy was used for these patients until
progression.
The median number of resected lymph nodes was 12 (1
to 36). The median number of positive lymph nodes was
2 (1 to 28). Forty-two patients presented at least one
extracapsular extension (50.6%). The median total dose
was 50 Gy (30 to 70 Gy). For a majority of treatments (37
patients; 63.8%) a standard fractionation regimen was
used. The median dose/fraction was 2 Gy (1.8 to 3 Gy).
The median number of fractions was 25 (10 to 44 frac-
tions). Patients were treated with five fractions/week.
The median biological equivalent dose (BED with a/b =
2G y )w a s5 0G y( 1 8t o7 1G y ) .
Median follow-up was 73 months (2 to 158 months).
18 patients were lost to follow-up.
Overall survival
Survival analysis was performed from the admitted date
of lymph node recurrence. 43 patients (47.8%) died from
an evolution of melanoma. Median survival after lymph
node recurrence was 31.8 months ([CI] 23.3 to 40.3
months).
Regional control
16 patients (22.5%) presented a recurrence within the
treated area.
Prognostic factors
Regional control
Age (p = 0.2), sex (p = 0.64), initial site (p = 0.32), Bre-
slow index (p = 0.88), Clark index (p = 0.7), number of
resected lymph nodes (p = 0.2), number of metastatic
lymph nodes (p = 0.88), and size of metastatic lymph
node greater than 3 cm (p = 0.64) were not significantly
associated with worse regional control. Extracapsular
extension was significantly associated with worse regio-
nal control (p = 0.019).
Overall survival
The following putative predictive factors were consid-
ered for the analysis: sex (p = 0.059), age (p = 0.3), time
between initial cutaneous melanoma diagnosis and
relapse (0.49), initial site (0.12), relapse site (0.25),
Table 1 Patients, tumors and lymph nodes characteristic according to treatments (surgery alone vs surgery followed
by radiation therapy)
Characteristic Surgery Surgery + radiotherapy
No of patients 26 (group 1) 60
Dose <50 Gy = 30
(group 2)
Dose >50 Gy = 30
(group 3)
Age (y)* 55 (27-87) 52 (18-87)
Sex (F/M) 9/16 20/41
Interval ME-NM (y)* 1(0-14) 1(0-12)
Metastatic LN site (No of patients)
Cervical 4 17
Axillary 4 22
Inguinal 18 21
Primary tumor
Unknown 0 1
Breslow Index* 2.475 (0.38-33) 2.5 (0.15-33)
Clark Level* 4 (4-3) 4 (1-5)
Ulceration 3 9
Lymph node dissection
Number of resected LN* 11 (1-35) 11 (1-36)
Number of positive LN* 1 (1-9) 2 (2-28)
ECE* 1(0-3) 1 (0-11)
Number of patients with LN size >3 cm 13 23
* Median.
Abbreviations: ME = Melanoma excision; NM = Node metastases; ECE = extracapsular extension; LN = lymph nodes.
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lymph node size greater than 3 cm (p = 0.2). Extracap-
sular extension was significantly associated with a worse
survival (p = 0.03; figure 2).
Outcome of patients with and without radiotherapy
Radiation therapy did not improve regional control (p =
0.17) or overall survival (p = 0.18). Patients treated with a
total dose >50 Gy (group 3) had better regional control
(p = 0.004; figure 3) and overall survival (p = 0.005;
figure 4) than patients treated by surgery alone (group 1).
Regional control rates for each tumour location were
(radiation therapy >50 Gy vs. without radiation therapy):
90% vs. 70% for axillary LN metastasis, 80% vs. 72% for
inguinal LN metastasis and 85% vs. 50% for cervical LN
metastasis.
No statistical difference was found for regional control
between the three LN metastasis locations (p = 0.4).
Impact of radiotherapy after stratification according to
the identified prognostic factor
An analysis stratified on extracapsular extension showed
that patients with extracapsular extension treated with
surgery followed by radiation therapy with a total dose
≥50 Gy (group 3) experienced a better regional control
than those treated by surgery followed by adjuvant
radiotherapy with a total dose <50 Gy (group 2): 80% vs.
35% at 5-year follow-up (p = 0.03; figure 5). This differ-
ence was not found for patients without extracapsular
extension (p = 0.8).
Toxicity
Grade 1 toxicity was found in 5 patients (5.5%). Grade 2
toxicity was found in 21 patients (23.3%): 6 patients
(27.3%) treated with only surgery and 15 patients (22%)
treated with surgery followed by radiation therapy.
There was no grade 3 toxicity. Two patients (8.3%) trea-
ted for cervical LN metastasis, 4 patients (19%) treated
for axillary LN metastasis and 15 patients (39.5%) for
inguinal LN metastasis had grade 2 toxicity. Toxicity
rates were 9% grade 1 and 9% grade 2 for cervical, 20%
grade 2 for axillary and 45% for inguinal nodal regions.
There was a statistical increase in toxicity for patients
treated for groin metastases (p = 0.01) compared to other
treated areas, whichever treatment was performed (surgery
alone or surgery followed by radiation therapy). No statisti-
cal correlation between radiation therapy and higher toxi-
city was found for cervical and inguinal regions (p > 0.05).
There were more grade 2 toxicities for the axillary region
when radiation therapy was used (p = 0.047). Dose >50 Gy
was also not associated with higher toxicity (p = 0.36).
Discussion
Our analysis aimed to identify the patient subgroups that
could benefit from adjuvant radiation therapy. Extracap-
sular extension was the only significant prognostic factor
for regional control and overall survival. Patients with
this anatomopathologic feature were those who benefited
the most from adjuvant radiation therapy. Our results are
consistent with previous publications [13,14].
Figure 2 Extracapsular extension was significantly associated
with a worse overall survival (p = 0.03).
Figure 3 Radiation therapy with a total dose of more than 50
Gy was associated with better regional control (p = 0.004).
Figure 4 A total dose of more than 50 Gy was associated with
better overall survival (p = 0.005) for patients treated with
surgery followed by radiation therapy.
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In our study, regional control rate was 85% for cervical
nodal metastasis for patients treated with surgery fol-
lowed by radiotherapy. Recurrence rates for metastatic
melanoma in cervical lymph nodes range from 30 to 50%
after neck dissection alone [15-18]. Postoperative radio-
therapy leads to regional control rates of about 90% for
high-risk cervical metastases [19-21]. However, treat-
ment-related morbidity is an issue with adjuvant RT.
Toxicity was still very low for our patients: 9% grade 1
and 9% grade 2 toxicities. Ballo et al reported that 10% of
patients had complications that required medical inter-
vention at 5 years (ipsilateral hearing loss, hypothyroid-
ism, wound breakdown and bone exposure) [10].
Axillary nodal regions
Regional control rate in our study was 90% for patients
treated with surgery and radiation therapy for axillary
nodal regions. Axillary lymph node recurrence rates range
from 23 to 50% [22,23]. Toxicity in our study was higher
than that found for cervical nodal regions (20% grade 2
toxicity). Beadle et al reported treatment-related complica-
tions in 32% of patients treated with the hypofractionated
regimen (30 Gy in five fractions, twice-weekly) after 5
years [11]. Lymphoedema occurred in 42 of 200 patients
and was the most common complication. A study pub-
lished by Starritt et al on lymphoedema occurrence in 107
patients treated with axillary dissection alone or axillary
dissection plus postoperative radiation therapy [24]
reported that lymphoedema occurred in 10% of patients
who received dissection alone and in 53% treated with
radiotherapy (p < 0.005). The hypofractionated regimen
used in this study might explain this high rate.
Inguinal nodal regions
The regional control rate for our patients treated with
surgery and radiotherapy was 80%. However, the grade
2 toxicity rate was (45%). It is therefore important to
select patients with high-risk anatomopathological fea-
tures such as: extracapsular extension, 2 or more
involved lymph nodes, or large nodal disease. Inguinal
lymph node recurrence rates range from 19 to 40% of
patients treated with dissection [17,25]. Ballo et al (8)
reported a 3-year regional control of 74% in patients
treated for high-risk inguinal nodal metastases with 30
Gy at 6 Gy per fraction. Complications are more com-
mon than in other tumour locations: 25 to 45% of
patients were reported to develop lymphoedema
[1,15,26-29]. Obesity (BMI >25 kg/m2) entailed higher
rates of treatment-related complications (55%).
Radiobiology of melanoma
Melanomas in vitro seem less radiosensitive than other
tumour cell lines, but actually have a wide range of sen-
sitivities [30-32]. Overgaard analyzed the radiation
response of a clinical series of more than 600 metastatic
melanoma lesions, mainly skin metastases [33]. One of
the conclusions was that the response rate was depen-
dent on the size of the fraction, with complete response
rates of 57% when fractions of more than 4 Gy were
used. This has led many to advocate a hypofractionated
radiation therapy regimen. However, RTOG 83-05, the
only study designed to assess whether a high dose per
fraction irradiation was preferable in melanoma treat-
ment, showed no difference in regional control between
conventional and hypofractionated schedules [34]. A
more recent study published in 2009 by Strojan et al
[12] opted for more conventionally fractionated radio-
therapy schedules (2-2.5 Gy/fractions).
Our study would also lead us to believe that a more
conventionally fractionated schedule could be used (1.8
to 2.5 Gy) with a higher total dose (>50 Gy) in order to
minimize toxicities. However, its unicentric, retrospec-
tive design and the limited number of patients included
limits the interpretation of our results (our low toxicity
rates might be underevaluated), even if our groups of
patients were well balanced.
Overall, we would recommend using adjuvant radia-
tion therapy for patients with lymph node metastases
from cutaneous melanoma, especially if they present
one or more LN with extracapsular extension. Total
dose should be strictly greater than 50 Gy for this kind
of treatment, with a standard fractionation regimen (ex:
2 Gy/fraction, 5 fractions a week) in order to maximize
the efficacy and to minimize the toxicity. An even better
approach would be to use the biological equivalent dose
(BED), which should be greater than 50 Gy.
Conclusion
Melanoma is often considered to be a radioresistant
tumour. Our data, in accordance with previously reported
Figure 5 Radiation therapy with a dose greater than 50 Gy
was associated with better regional control (p = 0.03) for
patients with extracapsular extension.
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regional control. However, since toxicity is not negligible,
especially for axillary and inguinal lymph nodes, this treat-
ment should be considered only for patients with poor
anatomopathological features. The first factor that should
be taken into account is extracapsular extension.
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